Thornton, Pennsylvania, United States
John O’Donnell has led diverse global teams, with a budgets of over $150M, dedicated to defining, developing and delivering evidence of value to ensure patients, payers and providers have the best possible information about, and optimal access to innovative medicines. Over his career he has developed, launched and commercialized over 20 medicines in respiratory, cardiovascular, HCV, genito-urinary, transplant, diabetes, and oncology including the industry-leading medicines in immuno-oncology. Dr. O’Donnell is a leader in HEOR, Market Access and Health Technology Assessment with work experience in the US, Europe and Asia, and as a regional Head based in the US and UK. He is former Chair Academy Health's Corporate Council, former Chair of the Institutional Council of ISPOR, and was the lead author of the Value in Health Special Issues, HTA in Evidence-Based Health Care Reimbursement Decisions Around the World and Personalized Medicine and the Role of HEOR. He also founded the successful CoE - Center for Observational Research and Data Sciences. He holds a Doctorate in health policy and administration from the University of North Carolina at Chapel Hill. He has thirty years of experience in health services and outcomes research in industry, in academia and in US State and Federal governments, with twenty years of experience in the pharmaceutical industry. While in government and academia, he advanced health policy research in rehabilitation services, veterans’ health and the aged through his work with the US DVA and Duke University’s Center for the Study of Aging. He also analyzed optimal social service and primary care delivery models for foster care and geriatric team care. He is Adjunct Professor at the University of North Carolina at Chapel Hill, has published in the areas of health economic evaluation, health policy, health services research, geriatrics and rehabilitation and is a reviewer for a number of leading journals.